NHO Revive lands Nebraska’s only prostate cancer trial site

NHO Revive in Lincoln is now the only Nebraska site for a Johnson & Johnson Phase 3 prostate cancer trial testing the immune therapy pasritamig. The study could give patients with advanced disease access to a treatment designed to target cancer cells with a different approach than chemotherapy or hormone therapy.

Why it matters: - The trial gives Nebraska patients access to a Phase 3 study of a new immune-based prostate cancer treatment without leaving the state. - Pasritamig is designed to help T-cells target prostate cancer cells that express KLK2, a protein linked to the disease. - The study could offer a new option for patients whose cancer has progressed after standard treatments.

What happened: - NHO Revive became Nebraska’s only site for the Johnson & Johnson-sponsored KLK2-PASenger Phase 3 trial. - The site is in Lincoln through Nebraska Hematology Oncology and Revive Research Institute. - The announcement was dated July 22, 2026. - Dr. Kailash Mosalpura, medical oncologist at Nebraska Hematology-Oncology, said the trial brings innovative treatment options directly to patients in Lincoln and helps advance cancer care.

The details: - The randomized, open-label study compares pasritamig plus docetaxel with docetaxel alone. - The main goal is to see whether the combination extends the time patients live without their disease progressing on imaging scans. - Researchers will also measure overall survival, quality of life and other response outcomes. - Eligible participants must have histologically confirmed metastatic prostate adenocarcinoma. - Eligible patients must have disease that has progressed despite androgen deprivation therapy and at least one prior novel hormonal therapy. - Participants must be 18 or older and have an ECOG performance status of 0 or 1. - NHO Revive is a joint initiative between Nebraska Hematology Oncology and Revive Research Institute. - Nebraska Hematology Oncology has served Lincoln and surrounding communities since 1997. - NHO says its clinic includes seven physicians, 13 advanced practice providers and more than 145 staff. - The clinic says it was the first QOPI-certified and Oncology Medical Home APC4-certified clinic in Nebraska. - More information is available at the company’s announcement.

Between the lines: - The trial reflects a broader push to test therapies that redirect the immune system rather than rely only on chemotherapy or hormone suppression. - Nebraska’s only-site status suggests NHO Revive is being used as a regional access point for a highly specific late-stage cancer study. - The eligibility rules point to a patient group with advanced disease and limited remaining standard options.

What's next: - NHO Revive will enroll eligible patients for the Phase 3 study. - The trial will track whether pasritamig plus docetaxel improves outcomes enough to support broader use. - Johnson & Johnson and trial investigators will follow survival, imaging and quality-of-life data as the study continues.

The bottom line: - NHO Revive’s new role could expand access to a potentially new prostate cancer therapy for Nebraska patients while helping test whether immune targeting can improve outcomes in advanced disease.